Investors add $17M to Emulate Series B as Covance partners; UMass professor to work with Spark on next-gen vectors
Emulate has topped up its B round with a fresh injection of $17 million, bringing the total to $45 million. The biotech has been developing organs-on-a-chip tech that are being used to supplement, and perhaps one day replace, animals in preclinical research. The big CRO Covance, meanwhile, has signed up to start to integrate Emulate’s kidney-on-a-chip tech into its drug evaluation work.
Spark Therapeutics is partnering up with University of Massachusetts Professor Guangping Gao to pursue next-gen viral vectors that can work as better delivery vehicles for future gene therapies for the retina, liver and central nervous system. “These next-generation AAV vectors, Gao says, will be designed to “deliver genetic information to certain cell types more efficiently and to cell types that are otherwise hard to target.”
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters